RINVOQ Market Drug Insight and Market Forecast - 2032

“RINVOQ Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about RINVOQ for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the RINVOQ for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the RINVOQ for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RINVOQ market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Upadacitinib (ABT-494) - discovered and developed by AbbVie scientists and marketed as RINVOQ - is a selective and reversible JAK inhibitor that was approved by FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.

The European Commission in August 2021 approved RINVOQ to treat adults (15 mg and 30 mg) and adolescents (15 mg) with Atopic Dermatitis (AD). In January 2022, the US FDA approved Rinvoq for the treatment of moderate to severe AD in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the RINVOQ description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on RINVOQ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the RINVOQ research and development activities in atopic dermatitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around RINVOQ.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for RINVOQ in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RINVOQ Analytical Perspective

In-depth RINVOQ Market Assessment

This report provides a detailed market assessment of RINVOQ for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

RINVOQ Clinical Assessment

The report provides the clinical trials information of RINVOQ for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RINVOQ dominance.
• Other emerging products for atopic dermatitis are expected to give tough market competition to RINVOQ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RINVOQ in atopic dermatitis.
• This in-depth analysis of the forecasted sales data of RINVOQ from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RINVOQ in atopic dermatitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of RINVOQ?
• What is the clinical trial status of the study related to RINVOQ in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RINVOQ development?
• What are the key designations that have been granted to RINVOQ for atopic dermatitis?
• What is the forecasted market scenario of RINVOQ for atopic dermatitis?
• What are the forecasted sales of RINVOQ in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to RINVOQ for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?

This product will be delivered within 2 business days.